TCM Biotech International Corp. Stock

Equities

4169

TW0004169008

Pharmaceuticals

End-of-day quote Taipei Exchange 06:00:00 2024-06-06 pm EDT 5-day change 1st Jan Change
57.2 TWD +0.18% Intraday chart for TCM Biotech International Corp. -0.17% -1.72%
Sales 2024 * 1.08B 33.54M Sales 2025 * - Capitalization 3.38B 105M
Net income 2024 * 34M 1.05M Net income 2025 * - EV / Sales 2024 * 3.2 x
Net Debt 2024 * 86M 2.67M Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
79.4 x
P/E ratio 2025 *
-
Employees -
Yield 2024 *
0.1%
Yield 2025 *
-
Free-Float 99%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.18%
1 week-0.17%
1 month+3.62%
3 months+4.19%
6 months-3.05%
Current year-1.72%
More quotes
1 week
55.80
Extreme 55.8
57.30
1 month
52.10
Extreme 52.1
57.50
Current year
49.75
Extreme 49.75
61.00
1 year
49.75
Extreme 49.75
71.41
3 years
26.39
Extreme 26.3924
71.41
5 years
18.35
Extreme 18.3485
71.41
10 years
17.37
Extreme 17.3685
71.41
More quotes
Managers TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 08-08-25
Chairman - 10-06-22
Members of the board TitleAgeSince
Director/Board Member - 12-02-14
Chairman - 10-06-22
Director/Board Member - -
More insiders
Date Price Change Volume
24-06-07 57.2 +0.18% 62,433
24-06-06 57.1 -0.17% 149,533
24-06-05 57.2 0.00% 63,810
24-06-04 57.2 -0.17% 105,715

End-of-day quote Taipei Exchange, June 06, 2024

More quotes
TCM BIOTECH INTERNATIONAL CORP. is a Taiwan-based company principally engaged in the detection and development of new medicine for liver disease. The Company's main businesses include the development of new medicine, which are mainly used for the treatment of hepatitis C and non-alcoholic fatty liver and other disease, manufacture and sales of dietary supplements and botanical raw materials, the sales of western medicine products and medical equipment, which are mainly used for the treatment of orthopedic disorders, cardiovascular disorders, oncology disorders and others, sales agent of organic products. The Company distributes its products both in domestic markets and to overseas markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
57.2 TWD
Average target price
113 TWD
Spread / Average Target
+97.55%
Consensus